Inflammatory bowel disease: clinical aspects and established and evolving therapies
By Daniel C. Baumgart, W. Sandborn. The Lancet, 2007
1,910 citations recorded by the source corpus.
Subfields: Epidemiology, Genetics, Surgery
View Paper: https://www.semanticscholar.org/paper/f0f032e96cd12c48e4b900663fd50ee197908e99
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Genetics
- W. Sandborn
- J. Colombel
- S. Hanauer
- G. Lichtenstein
- B. Feagan
- P. Rutgeerts
- Bruce E. Sands
- Joel T. Dudley
In Surgery
Citations in the corpus
- The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics (2021, background): “CD mostly occurs in the small and large intestine, but it can also affect the mouth, esophagus, stomach, and anus, while CD commonly affects the colon and the rectum [42,43].”
- Macrophage activation by endogenous danger signals (2008, background): “Th17 T cells belong to a novel group of CD4+ T helper cells that are found highly up-regulated in the gut of IBD mice and which have been implicated in the pathology of IBD.”
- Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. (2011, background): “Twenty-seven placebo-treated patients (1 0], 6 [1], 17 [2], and 3 [3]) had a colectomy through 54 eeks.”
- Innate and adaptive immunity in inflammatory bowel disease. (2014, background): “The medical management includes corticosteroids, immunosuppressant agents and biologic therapies (such as different anti-tumor necrosis factor (TNF)-α compounds) [5].”
- Expanded Adipose-Derived Stem Cells for the Treatment of Complex Perianal Fistula: a Phase II Clinical Trial (2009, background): “Particularly in patients with fistula-in-ano associated with Crohn’s disease, recurrence is a distressing complication that significantly reduces quality of life.(5) Recent improvements in Presented in part at United European Gastroenterology Week, Paris, October 27 to 31, 2007; at the meeting of th”
- Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease (2011, background): “Because topiramate is already established as a safe and effective drug for treating neurological diseases in humans, and the side effect profile is generally more favorable than that ofmost drugs typically used to treat IBD (2, 17), these results suggest that additional clinical investigation into t”
- Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. (2012, neutral): “Nasopharyngitis 1 (2) 2 (6) 1 (3) 1 (3) 1 (2)”